目的 探讨丹参酮Ⅱ_A磺酸钠注射液联合甲磺酸酚妥拉明注射液治疗肺源性心脏病加重期的临床疗效。方法 选取2016年7月-2017年7月西电集团医院收治的肺源性心脏病急性加重期患者78例为研究对象，按照随机分组设计将研究对象分为对照组和治疗组，每组各39例。对照组静脉滴注甲磺酸酚妥拉明注射液，20 mg加入到5%葡萄糖注射液250 mL中，1次/d。治疗组在对照组的基础上静脉滴注丹参酮Ⅱ_A磺酸钠注射液，50 mg加入到0.9%氯化钠溶液250 mL中，1次/d。两组患者连续治疗14 d。观察两组的临床疗效，比较两组的血液流变学指标、心功能指标和血气指标。结果 治疗后，对照组和治疗组的总有效率分别为74.4%、92.3%，两组比较差异有统计学意义（P<0.05）。治疗后，两组全血高切黏度、全血低切黏度、血浆黏度、纤维蛋白原、红细胞积压均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显低于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组左心室射血分数（LVEF）、每搏输出量（SV）、一氧化碳（CO）均显著升高，平均肺动脉压（mPVP）均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组动脉血氧分压（pO₂）水平均显著升高，动脉血二氧化碳分压（pCO₂）水平均显著降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标的改善程度明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 丹参酮Ⅱ_A磺酸钠注射液联合甲磺酸酚妥拉明注射液治疗肺源性心脏病加重期具有较好的临床疗效，可改善心脏功能，改善血液流变学指标和血气指标，安全性较好，具有一定的临床推广应用价值。

Objective To study the clinical effect of Tanshinone Ⅱ_A Sulfonate Sodium Injection combined with Phentolamine Mesylate Injection in treatment of acute exacerbation of pulmonary heart disease. Methods Patients (78 cases) with acute exacerbation of pulmonary heart disease in Xi'an XD Group Hospital from July 2016 to July 2017 were randomly divided into control and treatment groups, and each group had 39 cases. Patients in the control group were iv administered with Phentolamine Mesylate Injection, 20 mg added into 5% glucose solution 250 mL, once daily. Patients in the treatment group were iv administered with Tanshinone Ⅱ_A Sulfonate Sodium Injection on the basis of the control group, 50 mg added into normal saline 250 mL, once daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and hemorheological indexes, heart function indexes, and blood gas indexes in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.4% and 92.3%, respectively, and there was difference between two groups (P<0.05). After treatment, whole blood high shear viscosity, whole blood low shear viscosity, plasma viscosity, fibrinogen, and erythrocyte backlog in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly lower than those in the control group, with significant difference between two groups (P<0.05). After treatment, LVEF, SV, and CO in two groups were significantly increased, but the mPVP in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of pO₂ in two groups were significantly increased, but the levels of pCO₂ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Tanshinone Ⅱ_A Sulfonate Sodium Injection combined with Phentolamine Mesylate Injection has clinical curative effect in treatment of acute exacerbation of pulmonary heart disease, can improve heart function, regulate hemorheological index and blood gas index, with good safety, which has a certain clinical application value.